Catalog No.
Product Name
Application
Product Information
Citations
-
Drug-Linker Conjugates for ADC
Val-Ala-PABC-N(Mesylpropane)-Exatecan is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features Exatecan, a potent inhibitor of DNA topoisomerase I, linked via a cleavable Val-Ala-PABC-N(Mesylpropane) moiety. It is intended for research applications focused on targeted cancer therapies, enhancing the selectivity and efficacy of antitumor agents. -
Drug-Linker Conjugates for ADC
DM1-MCC-PEG3-Biotin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound effectively links the potent cytotoxic agent DM1 with biotin via a stable MCC (maleimidocaproic acid) and PEG3 spacer, facilitating targeted delivery of therapeutics by conjugating to biotin-binding antibodies. It is particularly valuable in research focused on developing and optimizing ADCs for cancer treatment, enabling enhanced therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugates for ADC
Mal-Val-Ala-amide-(3)PEA-PNU-159682 is a drug-linker conjugate designed for targeted antibody-drug conjugate (ADC) applications. This compound features an ADC linker, Mal-Val-Ala-amide-(3)PEA, which is covalently bonded to the cytotoxic agent PNU-159682, exhibiting notable anti-tumor activity. It is suitable for research into cancer therapies, utilizing precise delivery mechanisms to enhance therapeutic efficacy while minimizing off-target effects. -
Antibody-Drug Conjugates
Ifinatamab deruxtecan is an antibody-drug conjugate that targets B7-H3, linking an anti-B7-H3 antibody to the DNA topoisomerase I inhibitor DXd. This compound exhibits significant antitumor activity, making it a valuable tool for research in oncology. It is particularly relevant for studies focused on targeted delivery of therapeutic agents in cancer treatment. -
Antibody-Drug Conjugate
Tisotumab vedotin is an antibody-drug conjugate (ADC) that targets tissue factor (TF). This compound is designed by covalently linking a fully human monoclonal antibody (TF-011) to the microtubule disruptor Monomethyll Auristatin E (MMAE) through the VcMMAE linker. Tisotumab vedotin exhibits immunomodulatory and anti-tumor activities, making it a valuable tool for researching advanced or metastatic solid tumors, including cervical cancer. -
Antibody-Drug Conjugate
Farletuzumab ecteribulin is an antibody-drug conjugate (ADC) that targets the folate receptor alpha (FRA) using the humanized anti-FRA antibody Farletuzumab. Conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin, this compound features an agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin exhibits significant cytotoxicity towards FRA-positive cancer cells and demonstrates potent antitumor activity, making it a valuable reagent for research in targeted cancer therapies. -
ADC Cytotoxin
Exatecan Intermediate 2 is an important precursor in the synthesis of Exatecan, a camptothecin analog with potent anticancer properties. This compound targets DNA, disrupting the proliferation and division of tumor cells, thereby inhibiting tumor growth. It is primarily employed in research focused on various cancers, including ovarian, lung, and breast cancers, making it a valuable tool in oncology studies. -
ADC Cytotoxin
Cyclopropaneacetamide-Exatecan is an analogue of Exatecan, functioning as an ADC (antibody-drug conjugate) cytotoxin. Its primary mechanism involves targeting cancer cells to deliver cytotoxic agents selectively, enabling effective tumor treatment. This compound is instrumental in the synthesis of ADC molecules and is valuable for research applications focused on cancer therapeutics and drug delivery systems. -
ADC Cytotoxin
7-MAD-MDCPT is a potent Camptothecin analog designed as a cytotoxic agent in antibody-drug conjugates (ADCs). Its primary mechanism involves the inhibition of topoisomerase I, leading to DNA damage and subsequent apoptosis in proliferating cells. This compound is utilized in the development of targeted cancer therapies, enhancing the effectiveness and specificity of ADCs in oncology research. -
ADC Cytotoxin
PBD-monoamide, a modified pyrrolobenzodiazepine (PBD) dimer, serves as an antibody-drug conjugate (ADC) cytotoxin. This compound exhibits DNA-binding activity, leading to reduced cell viability, making it a valuable tool for cancer research. PBD-monoamide is utilized in the synthesis of DHES0815A, an ADC targeting HER2, facilitating the study of targeted cancer therapies. -
ADC Cytotoxin/TopI Inhibitor
ZD06519 is a potent ADC cytotoxin and a topoisomerase I inhibitor derived from camptothecin. It exhibits a significant bystander effect, effectively inhibiting various malignancies, including HER2-positive and FRα-overexpressing tumors. By interfering with DNA cleavage, relaxation, and reconnection, ZD06519 induces apoptosis in tumor cells. This compound is ideal for ADC synthesis and applications in cancer research. -
ADC cytotoxin
NMT-IN-7 is a potent inhibitor of N-myristoyl transferase (NMT), exhibiting IC50 values of 2.1 nM for HsNMT1M and 0.6 nM for SU-DHL-10 cells. This compound functions effectively as an antibody-drug conjugate (ADC) cytotoxin, demonstrating significant potential in targeted cancer therapy. Its selective inhibition of NMT may facilitate the study of myristoylation in biological processes and contribute to the development of novel therapeutic strategies. -
ADC Cytotoxin
Fmoc-MMAE is a protective group-conjugated derivative of monomethyl auristatin E (MMAE), functioning primarily as a tubulin inhibitor. This compound exhibits potent cytotoxicity, making it valuable in the design and development of antibody-drug conjugates (ADCs). Its application in ADC synthesis allows for targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. -
ADC Payload
(R)-Benzyl 2-cyclopropyl-2-hydroxyacetate is an ADC payload precursor, designed to facilitate the synthesis of pyrrolidines. This compound plays a crucial role in constructing targeted antibody-drug conjugates, enhancing the specificity and efficacy of therapeutic agents in cancer research. Researchers utilizing this reagent can explore advanced applications in drug development and improve therapeutic strategies. -
ADC Cytotoxin
N-Me-L-Ala-maytansinol is an ADC cytotoxin that serves as a potent cell-permeable payload for antibody-drug conjugates. It exhibits significant cytotoxic activity against target cells, making it a valuable reagent in cancer therapeutics research. This compound is instrumental in the development of targeted therapies by enhancing the selectivity and efficacy of ADCs in preclinical studies. -
ADC Cytotoxin
SC209, a 3-aminophenyl hemiasterlin derivative, targets tubulin as an ADC cytotoxin. This compound demonstrates reduced efflux potential through the P-glycoprotein 1 pump when compared to other tubulin-targeting agents, enhancing its efficacy in therapeutic applications. SC209 exhibits significant antitumor activity and is suitable for the synthesis of antibody-drug conjugates (ADCs), making it a valuable reagent in cancer research. -
ADC Cytotoxin
Duostatin 5 is an ADC cytotoxin that serves as a synthetic building block for antibody-drug conjugates (ADCs). It is derived from MMAF and allows for efficient conjugation to antibodies targeting 5T4 through a disubstituted C-Lock linker, enabling stable and straightforward synthesis. Duostatin 5 features an azide functional group, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted azide-alkyne cycloaddition (SPAAC) with DBCO or BCN groups. This reagent is valuable for researchers developing targeted therapies in cancer treatment. -
ADC Cytotoxin
Maytansinoid B is an ADC cytotoxin that specifically targets tubulin, acting as an antimitotic agent by inhibiting microtubule assembly. This compound can be conjugated with antibodies to form effective antibody-drug conjugates (ADCs), facilitating targeted cancer therapies. By inducing G2/M cell cycle arrest, Maytansinoid B promotes apoptosis in rapidly dividing cells, making it a valuable tool for cancer research and therapeutic applications. -
ADC Cytotoxin
N-Ac-γ-Calicheamicin-AcBut-NHS ester is an ADC cytotoxin that induces cell cycle arrest and apoptosis through the formation of DNA double-strand breaks. This compound is primarily utilized in the synthesis of antibody-drug conjugates (ADCs) and is particularly relevant in cancer research, including studies related to acute lymphoblastic leukemia (ALL) and various hematological malignancies. Its potent cytotoxic properties make it a valuable tool for advancing therapeutic strategies in oncology. -
ADC Cytotoxin
Hydrotecan is a derivative of Camptothecin, specifically designed as an antibody-drug conjugate (ADC) cytotoxin. It exhibits potent antitumor activity by inducing apoptosis in cancer cells through its action on topoisomerase I. This compound is valuable for the synthesis of ADC molecules, facilitating targeted cancer therapy research and development. -
ADC Cytotoxin
DC0-NH2 is an effector moiety targeting antibody-drug conjugates (ADCs) with enhanced stability compared to its analog DC1. This compound exhibits remarkable cytotoxicity, demonstrating approximately 1000-fold greater potency than traditional anticancer agents like Doxorubicin. The mechanism involves binding to the minor groove of DNA, leading to alkylation of adenine residues via its propabenzindole (CBI) moiety, making it a valuable candidate for cancer research and therapeutic applications. -
ADC Cytotoxin
DM3, a Maytansine analog, is a potent tubulin inhibitor that contains disulfide or thiol groups. As a key cytotoxic component of antibody-drug conjugates (ADCs), DM3 is designed to selectively target and eliminate cancer cells. Its ability to disrupt microtubule formation makes it valuable in cancer research and the development of targeted therapies. -
ADC Cytotoxin
7-MAD-MDCPT hydrochloride is a Camptothecin analog that serves as a cytotoxic payload in antibody-drug conjugates (ADCs). This compound demonstrates potent anti-cancer activity by targeting topoisomerase I, leading to DNA damage and subsequent apoptosis in cancer cells. It is primarily utilized in research focused on developing targeted cancer therapies and enhancing the efficacy of ADCs. -
ADC Cytotoxin
7-Aminomethyl-10-methyl-11-fluoro camptothecin is a potent cytotoxin targeting cancer cells through its mechanism of acting as a topoisomerase inhibitor. This compound serves as an essential intermediate for the synthesis of camptothecin-based antibody-drug conjugates (ADCs), which are designed to deliver targeted therapeutic agents to tumor cells. Its applications in cancer research support the development of innovative treatments aimed at improving the efficacy of chemotherapy while reducing systemic toxicity. -
ADC Cytotoxin
Tomaymycin DM is a derivative of tomaymycin that acts as a DNA alkylating agent, functioning primarily as a payload in antibody-drug conjugates (ADCs). This compound exhibits potent cytotoxic activity, targeting tumor cells through selective delivery mechanisms associated with ADCs. Tomaymycin DM is essential for research into targeted cancer therapies and the development of novel ADC formulations. -
ADC Cytotoxin
Exatecan Intermediate 2 hydrochloride is a cytotoxic agent targeting DNA through its mechanism as a camptothecin analog. This compound plays a critical role in the synthesis of Exatecan, an anticancer agent known for its efficacy against various malignancies, including ovarian, lung, and breast cancers. Exatecan Intermediate 2 hydrochloride is primarily utilized in research focused on cancer biology and therapeutic development. -
ADC Cytotoxin
Exatecan Intermediate 4, a key intermediate in the synthesis of Exatecan (DX-8951), functions as an ADC cytotoxin. This compound exhibits potent antitumor activity by disrupting DNA replication, leading to the inhibition of cancer cell proliferation. It is utilized in research related to various malignancies, including ovarian, lung, and breast cancers, providing insights into targeted cancer therapies and drug development. -
ADC Cytotoxin
PNU-159682 carboxylic acid is a potent cytotoxin utilized in antibody-drug conjugates (ADCs) targeting the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. This compound exhibits diverse biological activities, including modulation of cell adhesion, cell-cell signaling, and glycoprotein turnover. It plays significant roles in inflammation and immune response, making it valuable for research applications in oncology and immunology. -
ADC Cytotoxin
Maytansinoid DM4 is a thiol-containing maytansine derivative that serves as a potent cytotoxic agent. Acting as a key component in antibody-drug conjugates (ADCs), it exhibits significant biological activity by selectively targeting and destroying cancer cells. This compound is instrumental in advancing therapeutic strategies for cancer treatment research. -
ADC Payload
(1R,9S)-Dxd is an isomer of Dxd and serves as an antibody-drug conjugate (ADC) payload. Its primary mechanism involves targeted delivery of cytotoxic agents, enhancing the specificity and efficacy of ADCs in cancer therapy. This compound is utilized in the synthesis of various ADC formulations for research applications focused on improving therapeutic outcomes in oncology. -
ADC Cytotoxin
INX-SM-56 is a cytotoxin specifically designed for the synthesis of anti-VISTA antibody-drug conjugates. Targeting VISTA (V-region Immunoglobulin-containing Suppressor of T cell Activation), this compound enhances the cytotoxic efficacy of therapeutic antibodies. It is primarily utilized in cancer research to investigate immune modulation and therapeutic strategies against tumor progression. -
ADC Linker
DeBoc-Cabazitaxel serves as a versatile ADC linker, facilitating the conjugation of antibodies to cytotoxic agents for targeted therapy. This compound enhances the efficacy of antibody-drug conjugates (ADCs) by enabling selective delivery to tumor cells while minimizing off-target effects. It is particularly valuable in the development of novel cancer therapies, supporting research in targeted anti-tumor strategies. -
ADC linker
Dap-NE is an intermediate reagent specifically designed for use in the synthesis of antibody-drug conjugates (ADCs), particularly the cytotoxic agent Monomethyl auristatin E. Its role as a linker plays a critical part in ensuring the efficient delivery of therapeutic agents to targeted cells, enhancing the efficacy of the ADC. This compound is essential for researchers investigating novel ADC formulations and their applications in cancer therapeutics. -
ADC Cytotoxin
DMEA-PNU-159682 is an antibody-drug conjugate (ADC) cytotoxin that combines the metabolites of nemorubicin (MMDX) with the potent cytotoxic agent PNU-159682. This compound exhibits significant cytotoxicity, making it a valuable tool for targeted cancer therapies. Its unique mechanism of action allows for selective delivery of cytotoxic agents to tumor cells, thereby enhancing therapeutic efficacy while minimizing off-target effects in research applications focused on ADC development and optimization. -
ADC Cytotoxin
DC4 is an ADC cytotoxin utilized in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates targeted cancer therapy, enabling the selective delivery of cytotoxic agents to malignant cells while minimizing effects on healthy tissue. Its applications are particularly relevant in oncology research focused on enhancing the efficacy of cancer treatments through targeted delivery mechanisms. -
ADC Cytotoxin
DC4SMe is a phosphate proagent of the cytotoxic DNA alkylator DC4, designed for use in the synthesis of antibody-drug conjugates (ADCs). Exhibiting low IC50 values of 1.9 nM, 2.9 nM, and 1.8 nM against Ramos, Namalwa, and HL60/s cancer cell lines, respectively, DC4SMe demonstrates potent anti-cancer activity. This compound is suitable for research applications focused on targeted cancer therapies. -
ADC Cytotoxin
Diacetyl Agrochelin is an acetyl derivative of Agrochelin, targeting ADC cytotoxins for therapeutic applications. This compound demonstrates significant cytotoxic activity in various tumor cell lines, making it valuable for cancer research and development of targeted anticancer therapies. Its unique mechanism of action supports investigations into the efficacy of antibody-drug conjugates in oncological studies. -
ADC Payload
TNF-α Agonistic 2 is an agonist targeting tumor necrosis factor-alpha (TNF-α), functioning primarily as an antibody-drug conjugate (ADC) payload. This compound exhibits significant biological activity by reducing tissue thickness, as evidenced by its effects on murine models. It is applicable in research related to targeted cancer therapies and may facilitate the study of TNF-α's role in immune modulation and tumor microenvironment interactions. -
ADC Payload
Auristatin S is a potent antitumor agent designed as a payload for antibody-drug conjugates (ADCs). It exhibits significant cytotoxic activity while mitigating bystander effects and enhancing off-target toxicity profiles. Auristatin S demonstrates excellent tolerability in Karpas and KarpasBVR cell models, making it a valuable tool for targeted cancer therapies across various tumor types. Its unique properties support its application in the development of effective ADCs for cancer treatment research. -
ADC Cytotoxin
DMEA-PNU-159682 dichloroacetate acts as an antibody-drug conjugate (ADC) cytotoxin, incorporating metabolites of nemorubicin (MMDX) generated from liver microsomes along with the potent cytotoxic agent PNU-159682. This compound exhibits significant biological activity by selectively targeting cancer cells, enabling targeted delivery and enhanced therapeutic efficacy. DMEA-PNU-159682 is applicable in cancer research, specifically in studies focusing on ADC development and the evaluation of cytotoxic mechanisms. -
ADC Cytotoxin
Gly-Cyclopropane-Exatecan functions as a key component in the synthesis of antibody-drug conjugates (ADCs) targeting B7-H4. It incorporates Exatecan, a potent DNA Topoisomerase I inhibitor, into the ADC hu2F7-Exatecan, which has demonstrated significant antitumor efficacy in vivo and in vitro. This compound is relevant for cancer research, particularly in the development of targeted therapy strategies against tumor cells expressing B7-H4. -
ADC Cytotoxin
Muscotoxin A is an ADC cytotoxin that functions as a cytotoxic lipopeptide. It effectively permeabilizes mammalian cell membranes, leading to the induction of necrotic cell death. This compound is valuable in research applications involving targeted cancer therapies and the study of cellular responses to membrane disruption. -
ADC Cytotoxin
Dimethyl-SGD-1882 is a highly potent DNA alkylator, specifically designed for use as an antibody-drug conjugate (ADC) cytotoxin. It acts by forming covalent bonds with DNA, leading to the inhibition of DNA replication and subsequent induction of cytotoxicity in rapidly dividing cancer cells. This compound is valuable for research applications focused on targeted cancer therapies and the development of novel ADCs. -
ADC Cytotoxin
7-MAD-MDCPT TFA is a Camptothecin analog that serves as a cytotoxic payload for antibody-drug conjugates (ADCs). Its mechanism targets topoisomerase I, leading to the induction of apoptosis in malignant cells. This compound is relevant for research applications focused on cancer therapy, particularly in the development of targeted treatment strategies that enhance the efficacy of ADCs. -
ADC Payload
DUBA is a potent DNA alkylating agent that serves as an effective antibody-drug conjugate (ADC) payload. By covalently binding to DNA, DUBA disrupts replication and transcription processes, leading to cytotoxic effects in targeted cancer cells. Its application in synthesizing ADCs enables enhanced specificity and efficacy in delivering therapeutic agents directly to tumor sites, aiding in cancer research and treatment development. -
ADC Payload
Cryptophycin analog 1 is a potent antibody-drug conjugate (ADC) payload that targets and disrupts cancer cell proliferation. Exhibiting significant anticancer activity, this compound demonstrates cellular efficacy that is an order of magnitude greater than established ADC payloads such as MMAE and DM1. Its enhanced potency makes it a valuable tool for research in targeted cancer therapies. -
ADC Linker
Fmoc-Phe-Lys(Trt)-PAB-PNP is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic agents to antibodies while allowing for selective release in the target environment. Its design enables enhanced efficacy in targeted cancer therapy, making it a valuable tool for researchers developing ADCs. -
ADC linker
Aminoxyacetamide-PEG3-azide is a non-cleavable linker designed for antibody-drug conjugate (ADC) synthesis, targeting efficient conjugation in bioconjugation applications. This reagent features an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and is also suitable for strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups. Its versatile click chemistry capabilities make it an essential tool in the development of targeted therapeutics. -
ADC Linker
DBCO-PEG3-TCO is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs), featuring a 3-unit polyethylene glycol (PEG) spacer. This reagent facilitates click chemistry through its dibenzocyclooctyne (DBCO) moiety, enabling strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-functionalized compounds. Additionally, the TCO group supports inverse electron demand Diels-Alder (iEDDA) reactions with tetrazine-containing molecules, making DBCO-PEG3-TCO a versatile tool for advancing ADC development in therapeutic research. -
ADC Linker
m-PEG11-Amine is a cleavable linker designed for the functionalization of antibody-drug conjugates (ADCs). This polyethylene glycol (PEG)-based compound enhances solubility and stability of ADCs, facilitating targeted delivery of cytotoxic agents. In addition to its application in ADCs, m-PEG11-Amine is also suitable for the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation research.
